

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06829 A2

- (51) International Patent Classification⁷: **G01N 33/48**
- (21) International Application Number: **PCT/US01/22447**
- (22) International Filing Date: **18 July 2001 (18.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/219,067 18 July 2000 (18.07.2000) US
60/232,909 12 September 2000 (12.09.2000) US
60/278,550 23 March 2001 (23.03.2001) US
Not furnished 8 May 2001 (08.05.2001) US
- (71) Applicant: **CORRELOGIC SYSTEMS, INC.** [US/US];
Suite 300, 6701 Democracy Boulevard, Bethesda, MD
20817 (US).
- (72) Inventors: **HITT, Ben, A.**; 1910 Cuire Dr., Severn, MD
21144 (US). **PETRICOIN, Emanuel, F., III**; 2805 Feather
Ridge Ct., Dunkirk, MD 20754 (US). **LEVINE, Peter, J.**;
9608 Sotweed Dr., Potomac, MD 20854 (US). **LIOTTA,**
Lance, A.; 8601 Bradley Boulevard, Bethesda, MD 20817
(US).
- (74) Agent: **GLOVER, J., Gregory**; Ropers & Gray, Suite 800,
1301 K Street, N.W., Washington, D.C. 20005-3333 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).
- Published:**
— *without international search report and to be republished
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 02/06829 A2

(54) Title: A PROCESS FOR DISCRIMINATING BETWEEN BIOLOGICAL STATES BASED ON HIDDEN PATTERNS FROM BIOLOGICAL DATA

(57) Abstract: The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e.g., a biological sample from a human, e.g., serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirants, semen, vaginal fluids, pre-ejaculate.), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e.g., patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.

A Process for Discriminating between Biological States
based on Hidden Patterns from Biological Data

5

This application claims benefit under 35 U.S.C. sec. 119(e)(1) of the priority of applications Serial No. 60/232,909, filed September 12, 2000, Serial No. 60/278,550, filed March 23, 2001, Serial No. 60/219,067, filed July 18, 2000, and U.S. Provisional Application titled "A Data Method Algorithm Reveals Disease with Protein Signal of Ovarian and Prostate Cancer in Serum," (Serial. No. to be assigned),
10 filed May 8, 2001 which is hereby incorporated by reference in its entirety.

I. Field of the Invention

The field of the invention concerns a process for determining a biological state through the discovery and analysis of hidden or non-obvious,
15 discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (*e.g.*, a biological sample from a human, *e.g.*, serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate, *etc.*), *etc.* which is analyzed to
20 determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, *etc.*

Specifically, the invention concerns analytical methods that a) discover hidden discriminatory biological data patterns (*e.g.*, patterns of protein expression in a serum sample that classify the biological state of an organ) that are subsets of the
25 larger data stream, said discrimination implying the ability to distinguish between two or more biological states in a learning set of data and b) the application of the

aforementioned patterns to classify unknown or test samples. More specifically, the invention concerns a method for analysis of a data stream, which is derived from a physical or chemical analysis of molecules (*e.g.*, proteins, peptides, DNA, RNA, *etc.*) in the biological sample (*e.g.*, a mass spectrum analysis of the sample).

5 These patterns are defined as "hidden" because they are often buried within a larger highly complex data set and are not obvious or apparent to the eye or other current classification systems. The pattern itself can be defined as the combination of three or more values such that the position of the vectors in an n-dimensional space is discriminatory between biological states even when individual
10 values may not be discriminatory. The discriminatory patterns of the invention are novel because they can be defined without any knowledge of the identity or relationship between the individual data points in the biological data or any knowledge of the identity or relationship between the molecules in the biological samples.

15 One analytical method to discover such biological states comprises the application of two related heuristic algorithms, a learning algorithm and a diagnostic algorithm, wherein the parameters of the diagnostic algorithm are set by the application of the learning algorithm to a learning set of data such that two or more biological states may be distinguished. Such biological states may be the presence or
20 absence of a disease, efficacy or non-efficacy of a drug, toxicity or non-toxicity of a drug, *etc.* Although the invention is generic, specific implementations for diagnosis of various cancers (including, but not limited to carcinomas, melanomas, lymphomas, sarcomas, blastomas, leukemias, myelomas, neural tumors, *etc.*, and cancers of organs like the ovary, prostate, and breast.), presence of a pathogen, and toxicity are

disclosed. The preferred embodiment of the invention is the discovery and use of molecular patterns that reflect the current or future biological state of an organ or tissue. Another embodiment of the invention is the combination of data describing the molecular patterns of a biological state with other non-biological or clinical data
5 (e.g., psychiatric questioning) to yield a classification describing the health of a patient.

II. Background of the Invention

The detection of changes in biological states, particularly the early detection of diseases has been a central focus of the medical research and clinical
10 community. The prior art includes examples of efforts to extract diagnostic information from the data streams formed by physical or chemical analysis of tissue samples. These techniques are generically termed "data-mining." The data streams that have been mined are typically of two forms: analysis of the levels of mRNA expression by hybridization to DNA oligonucleotide arrays ("DNA microarrays") and
15 analysis of the levels of proteins present in a cell or in a serum sample, wherein the proteins are characterized either by molecular weight using mass spectroscopy or by a combination of molecular weight and charge using a 2-D gel technique.

Rajesh Parekh and colleagues have described protein based data-mining diagnosis of hepatocellular cancer using serum or plasma samples (WO
20 99/41612), breast cancer using tissue samples (WO 00/55628) and rheumatoid arthritis using serum or plasma samples (WO 99/47925). In each publication, a two dimensional gel analysis is performed. The analysis consists of measuring the levels of individual proteins as determined by the 2-D gels and identifying those proteins that are elevated or depressed in the malignant as compared to the normal tissue.

Liotta and Petricoin (WO 00/49410) provide additional examples of protein based diagnostic methods using both 2-D gels and mass spectroscopy.

However, the analysis of Liotta and Petricoin is similar to Parekh in that it consists of a search for specific tumor markers. Efforts to identify tumor markers have also been
5 performed using DNA microarrays. Logging, W.T., 2000, Genome Res. 10, 1393-02, describes efforts to identify tumor markers by DNA microarrays in glioblastoma multiforme. Heldenfalk, I., et al., 2001, New England J. Med. 344, 539, report efforts to identify tumor markers that distinguish the hereditary forms of breast cancer resulting from BRCA1 and BRCA2 mutations from each other and from common
10 idiopathic breast cancer by data-mining of DNA microarray data.

Alon et al., 1999, PNAS 96, 6745-50, describe the use of DNA microarray techniques to identify clusters of genes that have coordinated levels of expression in comparisons of colonic tumor samples and normal colonic tissue. These studies did, in fact, identify genes that were relatively over or under expressed
15 in the tumor compared to normal tissue. However, the clustering algorithm was not designed to be able to identify diagnostic patterns of gene expression other than a tumor marker type pattern.

Data-mining efforts directed towards indicators other than tumor markers have been used for diagnosis. These efforts routinely employ pattern
20 recognition methods to identify individual diagnostic markers or classify relationships between data sets. The use of pattern recognition methods to classify genes into categories based on correlated expression under a variety of different conditions was pioneered by Eisen, M., et al., 1998, PNAS 95, 14863-68; Brown, MPS, et al., 2000, PNAS 97, 262-67 and Alter, O., et al., 2000, PNAS 97, 10101-06. In general, these

techniques use a vector space in which each vector corresponds to a gene or location on the DNA micro array. Each vector is composed of scalars that individually correspond to the relative levels of expression of the gene under a variety of different conditions. Thus, for example, Brown et al. analyzes vectors in a 79 dimension vector space where each dimension corresponds to a time point in a stage of the yeast life-cycle and each of 2,467 vectors correspond to a gene. The pattern recognition algorithms are used to identify clusters of genes whose expression is correlated with each other. Because the primary concern is the correlation of gene expression, the metric that is employed in the pattern recognition algorithms of Eisen et al. and related works is a Pearson coefficient or inner product type metric, not a Euclidean distance metric. Once clustering is established, the significance of each cluster is determined by noting any common, known properties of the genes of a cluster. The inference is made that the heretofore uncharacterized genes found in the same cluster may share one or more of these common properties.

15 The pattern recognition techniques of Eisen et al. were applied by Alizadeh and Staudt to the diagnosis of types of malignancy. Alizadeh and Staudt began by constructing vectors, each corresponding to a gene, having scalars that correspond to the relative level of expression of the gene under some differentiation condition, e.g., resting peripheral blood lymphocyte or mitogen stimulated T cells.

20 The pattern recognition algorithm then clusters the genes according to the correlation of their expression and defines a pattern of expression characteristic of each differentiation state. Samples of diffuse large B-cell lymphomas (DLBCL) were then analyzed by hybridization of mRNA to the same DNA microarrays as used to determine the gene clusters. DLBCL were found to have at least two different gene

expression patterns, each characteristic of a normal differentiation state. The prognosis of the DLBCL was found to correlate with the characteristic differentiation state. Thus, the diagnostic question posed and answered in Alizadeh and Staudt was not benign or malignant but rather of determining the type or subtype of malignancy
5 by identifying the type of differentiated cell having a pattern of gene expression most similar to that of the malignancy. Alizadeh et al., 2000, Nature 403, 503-511. Similar techniques have been used to distinguish between acute myeloid leukemia and acute lymphocytic leukemia. Golub, T.R., et al., 1999, Science 286, 531-537.

Accordingly, it can be seen that data-mining methods based on the
10 physical or chemical analyses having large numbers, *i.e.*, greater than 1,000, of data points consist of two types: data-mining to identify individual markers such as genes or proteins having expression levels that are increased or suppressed in malignant cells of a defined type compared to normal cell; and data-mining wherein a pattern of known gene expression characteristic of a normal differentiated cell type is used to
15 classify a known malignant cell according to the normal cell type it most closely resembles.

Thus, there is a need for methods that can determine biological states using biological data other than single markers (such as tumor markers), or gene expression clusters. Usually, the role that single markers play in the pathology of a
20 disease must be known and established, quite often at great cost, prior to the analysis of a biological sample. Additionally, these markers are often localized in internal organs or tumors, and complex, invasive, localized biopsies must be performed to obtain biological samples containing such markers. Given the complexity of biological states such as a disease there is an exceptional need for the ability to

diagnose biological states using complex data inherent to such biological states without prior extensive knowledge of the relationship of molecules present in such samples to each other.

Additionally, gene expression cluster analysis is limited in scope
5 because such analysis incorporates an analysis of all expressed genes irrespective of whether the expression of such genes is causative or merely influenced by the causative action of those genes that are characteristic of the biological state. The clustering analysis does not incorporate solely those genes that are characteristic of the biological state of interest, but uses the entire range of data emanating from the
10 assay, thus making it complex and cumbersome. Furthermore, gene expression analysis must involve nucleic acid extraction methods, making it complex, and time-consuming. Pattern recognition algorithms when applied are also rendered difficult because the correlation of gene expression that is employed is a complex Pearson coefficient or inner product type metric, and not a simple Euclidean distance metric.

15 In contrast to the prior art, the current invention discovers optimal hidden molecular patterns as subsets within a larger complex data field, whereby the pattern itself is discriminatory between biological states. Thus, the current invention avoids all the aforementioned problems associated with the analytical methods disclosed in the prior art, and has the ability to discover heretofore unknown
20 diagnostic patterns. Such hidden molecular patterns are present in data streams derived from health data, clinical data, or biological data. Biological data may be derived from simple biological fluids, such as serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate,

etc., making routine sampling easy, although the expression of such molecular patterns are characteristic of disease states of remote organs. No prior knowledge of specific tumor markers or the relationship of molecules present in the biological sample to each other is required or even desired. The current invention also discloses
5 methods of data generation and analysis. Such methods of data analysis incorporate optimization algorithms in which the molecular patterns are recognized, and subjected to a fitness test in which the fitness pattern that best discriminates between biological states is chosen for the analysis of the biological samples.

III. Summary of the Invention

10 The invention comprises the use of pattern discovery methods and algorithms to detect subtle, if not totally hidden, patterns in the expression of certain molecules in biological samples that are potentially diagnostic in nature, or predictive of a biological state. In one embodiment of the invention such patterns of molecular expression are patterns of protein expression, particularly patterns of low molecular
15 weight proteins (*i.e.* less than 20,000 Da). Such hidden patterns of protein expression may be obtained from only a sub-set of the total data-stream provided to the algorithm, several subsets, or may be obtained from an analysis of the total data stream. The pattern can be defined as a vector of three or more values such that the position of the vectors in an *n*-dimensional space is discriminatory between biological
20 states even when individual values may not be discriminatory. The molecules of interest may be any relevant biological material such as proteins (full, cleaved, or partially expressed), peptides, phospholipids, DNA, RNA, *etc.*

The discriminatory patterns that discriminate between biological states are often small subsets of data hidden in the larger data stream derived from physical

or chemical analysis of the biological sample. Thus, in order to find such discriminatory patterns that distinguish between biological states, a means for finding an optimal set of features that make up the discriminatory pattern is required. The invention incorporates the process for finding this optimal set of features. A number of feature selection methods for discriminatory patterns may be used to practice the invention with varying degrees of classification success. These include, but are not limited to, statistical methods, stepwise regression methods, linear optimization methods, *etc.* However, statistical methods have some limitations in that they are often linear, at least in their simple, well-known forms such as multivariate linear regressions. Furthermore, statistical models tend not to be robust with respect to non-linear data. The number of independent variables a statistical model can successfully employ is generally ten or less, with a practical preferred limit of five or six. The preferred embodiment uses a method that couples the genetic algorithm, an evolutionary computation method, directly to an adaptive pattern recognition algorithm to efficiently find the optimal feature set. See U.S. Patent Application titled "Heuristic Method of Classification," (filing date: June 19, 2001, claiming priority of application Serial No. 60/212,404, filed June 19, 2000).

One method disclosed by this invention consists of two related heuristic algorithms, a diagnostic algorithm and a learning algorithm. The diagnostic algorithm is generated by the application of the learning algorithm to a learning (or training) data set. The learning data set is a data set formed from biological samples for which the biological state of interest is provided for the pattern discovery operation. For instance, the learning data set may comprise data taken from the sera of individuals with an established biopsy diagnosis, *e.g.*, a benign tumor and a

malignant tumor. This would enable the learning algorithm to find a signature pattern of proteins that could discriminate normal from cancerous sera samples.

In one embodiment, the method according to the invention begins by subjecting a biological sample to a high throughput physical or chemical analysis to obtain a data stream. Such data streams include, but are not limited to, mass spectral data of proteins found in the sample or in the intensity of mRNA hybridization to an array of different test polynucleotides. Generally, the data stream is characterized by a large number (10,000 or more) of intensities which are generated in a way that allow for the corresponding individual datum in data streams of different samples to be identified.

The first step of the diagnostic method is to calculate a vector, *i.e.*, an ordered set of a small number (between 2 and 20100, more typically between 5 and 208) that is characteristic of the data stream. The transformation of the data stream into a vector is termed "abstraction." In the present embodiments, abstraction is performed by selection of a small number of specific intensities from the data stream.

The second step of the diagnostic method is to determine in which, if any, data cluster the vector rests. Data clusters are mathematical constructs that are the multidimensional equivalents of non-overlapping "spheres" of fixed size in the vector space. Such data clusters are known as hyperspheres. The location and associated diagnosis of each data cluster is determined by the learning algorithm from the training data set. If the vector of the biological sample lies within a known cluster, the sample is given the diagnosis associated with that cluster. If the sample vector rests outside of any known cluster a diagnosis can be made that the sample does not meet that classification criteria or that it is of an unspecified atypia, *i.e.*, an

"atypical sample, NOS." For example, if a biological sample taken from a patient does not meet the classification of a malignant state for a specified cancer, it will be classified as non-malignant non-normal or of an unspecified atypia, "atypical sample, NOS."

5 The learning algorithm utilizes a combination of known mathematical techniques and two pre-set parameters. The user pre-sets the number of dimensions of the vector space and the size of the data clusters. Typically, the vector space is a normalized vector space such that the variation of intensities in each dimension is constant. Thus, the size of the cluster can be expressed as a minimum percent
10 similarity among the vectors resting within the cluster.

 In one embodiment, the learning algorithm contains of two generic parts, which have been developed by others and are well known in the field - - a genetic algorithm (J.H. Holland, *Adaptation in Natural and Artificial Systems*, MIT Press 1992) and a self-organizing adaptive pattern recognition system (T. Kohonen, *Self Organizing and Associative Memory*, 8 Series in Information Sciences, Springer Verlag, 1984; Kohonen, T, *Self-organizing Maps*, Springer Verlag, Heidelberg 1997
15). Genetic algorithms organize and analyze complex data sets as if they were information comprised of individual elements that can be manipulated through a computer driven natural selection process.

20 In the present invention, the search for hidden or subtle patterns of molecular expression that are, in and of themselves "diagnostic" is qualitatively different from those generated by prior art implementations of learning algorithms or data-mining techniques. Previous implementations of data-mining have identified specific molecular products that are indicative of a classification, *e.g.*, proteins or

transcripts that are elevated or depressed in pathological conditions. Thus, the level of the identified molecular products is termed per se diagnostic, because the level of the product is diagnostic without any further consideration of the level of any other molecular products in the sample, other than perhaps a normalizing molecular product that is used to normalize the level of the molecular products. One example of such per se diagnostic molecular products are tumor markers.

By contrast, in the data cluster analysis according to the invention, the diagnostic significance of the level of any particular marker, *e.g.*, a protein or transcript is a function of the levels of the other elements that are used to calculate the sample vector. Such products are termed hereinafter as contextual diagnostic products. Thus, in prior implementations of data-mining techniques, the likeness between the biological sample of interest and the learning data set was based on the specified groupings of the biological sample compared to the specified diagnostic molecular products. However, in the invention, the learning algorithm discovers wholly new classification patterns without knowing any prior information about the identity or relationships of the data pattern, *i.e.*, without prior input that a specified diagnostic molecular product is indicative of a particular classification.

The present invention is based, in part, on the unexpectedness or non-obvious discovery of finding hidden contextual diagnostic patterns to yield a classification, *e.g.*, the diagnosis of malignancy in cancers such as carcinomas, melanomas, lymphomas, sarcomas, blastomas, leukemias, myelomas, and neural tumors.

IV. Detailed Description of the Invention

The invention comprises a) creating a data stream representing the biological data (or combinations of data streams representing the biological data with clinical, health, or non-biological data) and abstraction of that data into characteristic
5 vectors; b) the discovery of hidden diagnostic patterns of molecular expression (*i.e.* pattern discovery); and c) determining which biological state of interest such a pattern of molecular expression represents. The molecules of interest may comprise, but are not limited to, proteins, peptides, RNA, DNA, etc. The biological samples comprise, but are not limited to serum, blood, saliva, plasma, nipple aspirants, synovial fluids,
10 cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate, *etc.*

The biological states of interest may be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, stage of a disease, biological state of an organ, presence of a pathogen (*e.g.*, a virus), toxicity of one or more drugs, *etc.*
15 The invention may be used for the diagnosis of any disease in which changes in the patterns of expression of certain molecules like proteins allow it to be distinguished from a non-diseased state. Thus, any disease that has a genetic component in which the genetic abnormality is expressed, one in which the expression of drug toxicity is observed, or one in which the levels of molecules in the body are affected may be
20 studied by the current invention. Such diseases include, but are not limited to, cancers (carcinomas, melanomas, lymphomas (both Hodgkin's and non-Hodgkin's type), sarcomas, blastomas, leukemias, myelomas, and neural tumors, such as glioblastoma, *etc.*), Alzheimer's disease, arthritis, glomerulonephritis, auto-immune diseases, *etc.*

Examples of carcinomas include, but are not limited to, carcinomas of the pancreas, kidney, liver and lung; gastrointestinal carcinomas.

The present invention is particularly valuable for the diagnosis of specific diseases for which early diagnosis is important, but is technically difficult because of the absence of symptoms, and for which the disease may be expected to produce differences that are detectable in the serum because of the metabolic activity of the pathological tissue. Thus, the early diagnosis of malignancies are a primary focus of the use of the invention.

The particular components of the invention are described below.

10 **A. Creation of the Data Stream**

The data stream can be any reproducible physical or chemical analysis of the biological sample that results in a high throughput data stream. Preferably, the high throughput data stream is characterized by 1,000 or more measurements that can be quantified to at least 1 part per thousand (three significant figures) and more preferably one part in 10,000. There exist numerous methods for the generation of data streams. In one embodiment of the invention when the molecules of interest are proteins or peptides, "time of flight" mass spectra of proteins may be used to generate a data stream. More specifically, matrix assisted laser desorption ionization time of flight (MALDI-TOF) and surface enhanced laser desorption ionization time of flight (SELDI-TOF) spectroscopy may be used when the molecules of interest are proteins or peptides. See generally WO 00/49410. In one embodiment, SELDI-TOF may be used to generate data streams for biological states representing toxicity, and detection of pathogens. In yet another embodiment, data streams may be generated using serially amplified gene expression (SAGE) for gene expression classification. In

some circumstances, data streams may be generated using 2-D Gels such as two-dimensional polyacrylamide gel electrophoreses (2D-PAGE).

For clinical pathology, the preferred patient sample for analysis is serum. However, biopsy specimens that are relatively homogenous may also be used.

- 5 For certain disease states, other fluids can be used, e.g., synovial fluid may be used in the differential diagnosis of arthritis or urine in the differential diagnosis of glomerulonephritis.

The particular proteins that are included in either SELDI-TOF and MALDI-TOF analysis depend upon the surface or matrix that is employed.

- 10 Lipophylic surfaces such as C-18 alkane surfaces are particularly convenient compared to anionic or cationic surfaces. However, those skilled in the art will appreciate that multiple spectra can be generated from the same sample using different surfaces. These spectra can be concatenated to yield "superspectra" which can be analyzed according to the invention. Likewise, data from two or more high
15 throughput assay methods can also be joined which can be analyzed by the invention. Furthermore, biological data as described in this invention can be joined with clinical, health, or non-biological data.

- Whatever surface, matrix or combination of surfaces and matrixes are to be used, great care must be exercised to ensure that the surfaces are uniform from
20 one biological sample to the next.

The data stream can also include measurements that are not inherently organized by a single ordered parameter such as molecular weight, but have an arbitrary order. Thus, DNA microarray data that simultaneously measures the expression levels of 2,000 or more genes can be used as a data stream when the tissue

sample is a biopsy specimen, recognizing that the order of the individual genes in the data stream is arbitrary.

Those skilled in the art will appreciate that in keeping with the available commercial embodiments of the instruments, the description of the invention considers the generation of the data stream from a biological sample and the abstraction of the data stream based on the optimal logical chromosome to be two separate processes. However, it is apparent that only routine design choices would allow for the measuring instrument itself to perform the abstracting function. This in no way changes the contribution of the invention to such a diagnostic method and the claims are to be construed as allowing the abstraction and vector analysis portions of the claimed diagnostic method to be performed on different computing devices.

It should be noted that a single data stream from a patient sample can be analyzed for multiple diagnoses using the method of the invention. The additional cost of such multiple analysis would be trivial because the steps specific to each diagnosis are computational only.

B. The Abstraction Process

The first step in the diagnostic process of the invention is the transformation or abstraction of the data stream into a characteristic vector. The data may be conveniently normalized prior to abstraction by assigning the overall peak an arbitrary value of 1.0 and, thus, all other points fractional values. For example, in the embodiment in which the data stream is generated by TOF Mass spectra, the most simple abstraction of TOF mass spectrum consists of the selection of a small number of data points. Those skilled in the art will recognize that more complex functions of multiple points could be constructed, such as averages over intervals or more complex

sums or differences between data points that are at predetermined distance from a selected prototype data point. Such functions of the intensity values of the data stream could also be used and are expected to function equivalently to the simple abstract illustrated in the working examples.

5 Those skilled in the art will also appreciate that routine experimentation can determine whether abstraction by taking the instantaneous slope at arbitrary points could also function in the present invention. Accordingly, such routinely available variations of the illustrated working examples are within the scope of the invention.

10 **C. Pattern Discovery**

 Pattern discovery is achieved by numerous methods as discussed in the Summary above. However, in a preferred embodiment, the pattern discovery comprises a diagnostic algorithm and a learning algorithm. Thus, in order to practice this embodiment of the invention the routine practitioner must develop a diagnostic
15 algorithm by employing a learning algorithm. To employ the learning algorithm, the routine practitioner uses a training data set and must select two parameters, the number of dimensions and the data cluster size. See U.S. Patent Application titled "Heuristic Method of Classification," (filing date: June 19, 2001, claiming priority of application Serial No. 60/212,404, filed June 19, 2000).

20 In one embodiment, the learning algorithm can be implemented by combining two different types of publicly available generic software, which have been developed by others and are well known in the field – a genetic algorithm (J.H. Holland, *Adaptation in Natural and Artificial Systems*, MIT Press 1992) that

processes a set of logical chromosomes¹ to identify an optimal logical chromosome that controls the abstraction of the data stream and a adaptive self-organizing pattern recognition system (see, T. Kohonen, *Self Organizing and Associative Memory*, 8 Series in Information Sciences, Springer Verlag, 1984; Kohonen, T, *Self-organizing Maps*, Springer Verlag, Heidelberg 1997), available from Group One Software, Greenbelt, MD, which identifies a set of data clusters based on any set of vectors generated by a logical chromosome. Specifically, the adaptive pattern recognition software maximizes the number of vectors that rest in homogeneous data clusters, i.e., clusters that contain vectors of the learning set having only one classification type.

10 The genetic algorithm essentially determines the data points which are used to calculate the characteristic vector. However, in keeping with the nomenclature of the art, the list of the specific points to be selected is termed a logical chromosome. The logical chromosome contains as many "genes" as there are dimensions of the characteristic vector. Any set of the appropriate number of data points can be a logical chromosome, provided only that no gene of a logical chromosome is duplicated. The order of the genes has no significance to the invention.

Genetic algorithms can be used when two conditions are met. A particular solution to a problem must be able to be expressed by a set or string of fixed size of discrete elements, which elements can be numbers or characters, and the

¹ The term logical chromosome is used in connection with genetic learning algorithms because the logical operations of the algorithm are analogous to reproduction, selection, recombination and mutation. There is, of course, no biological embodiment of a logical chromosome in DNA or otherwise. The genetic learning algorithms of the invention are purely computational devices, and should not be confused with schemes for biologically-based information processing.

strings can be recombined to yield further solutions. One must also be able to calculate a numerical value of the relative merit of each solution, namely its fitness. Under these circumstances, the details of the genetic algorithm are unrelated to the problem whose solution is sought. Accordingly, for the present invention any generic
5 genetic algorithm software may be employed. The algorithms PGAPack libraries, available from Argonne National Laboratory is suitable. The calculation of the fitness of any particular logical chromosome is discussed below.

In the illustrative examples, a training data set of about 100 sample data streams was used, each sample data stream containing about 15,000 data points.
10 The genetic algorithms were initialized with about 1,500 randomly chosen logical chromosomes. As the algorithm progressed, the more fit logical chromosomes are duplicated and the less fit are terminated. There is recombination between logical chromosomes and mutation, which occurs by the random replacement of an element of a logical chromosome. It is not an essential feature of the invention that the
15 initially selected collection of logical chromosome be random. Certain prescreening of the total set of data streams to identify those data points having the highest variability may be useful, although such techniques may also introduce an unwanted initialization bias. The best fitted pattern that survives this process is used to discriminate between biological states and determine the desired classification.

20 **D. The Pattern Recognition Process and Fitness Score Generation**

The fitness score of each of the logical chromosomes that are generated by the genetic algorithm is calculated. The calculation of the fitness score requires an optimal set of data clusters be generated for the given logical chromosome. Data clusters are simply the volumes in the vector space in which the

characteristic vectors of the training data set rest. The method of generating the optimal set of data clusters is not critical to the invention and will be considered below. However, whatever method is used to generate the data cluster map, the map is constrained by the following rules: (i) each data cluster should be located at the centroid of the data points that lie within the data cluster; (ii) no two data clusters may overlap; and (iii) the dimension of each cluster in the normalized vector space is fixed prior to the generation of the map.

As stated above, to employ the learning algorithm, the routine practitioner must use a learning data set and select two parameters, the number of dimensions and the data cluster size. Both parameters can be set using routine experimentation. Although there is no absolute or inherent upper limit on the number of dimensions in the vector, the learning algorithm itself inherently limits the number of dimensions in each implementation. If the number of dimensions is too low or the size of the cluster is too large, the learning algorithm fails to generate any logical chromosomes that correctly classify all samples into homogeneous clusters, and conversely if the number of dimensions can be too large. Under this circumstance, the learning algorithm generates many logical chromosomes that have the maximum possible fitness early in the learning process and, accordingly, there is only abortive selection. Similarly, when the size of the data clusters is too small, the number of clusters will be found to approach the number of samples in the training data set and, again, the routine practitioner will find that a large number of logical chromosomes will yield the maximum fitness.

Those skilled in the art understand that a training data set can nearly always be assigned into homogeneous data clusters. Thus, the value of the diagnostic

algorithm generated by a learning algorithm must be tested by its ability to sort a set of data other than the training data set. When a learning algorithm generates a diagnostic algorithm that successfully assigns the training data set but only poorly assigns the test data set, the training data is said to be overfitted by the learning
5 algorithm. Overfitting results when the number of dimensions is too large and/or the size of the data clusters is too small.

The method used to define the size of the data cluster is a part of the invention. The cluster size is defined by the maximum of the equivalent the Euclidean distance (root sum of the squares) between any two members of the
10 cluster. A data cluster size that corresponds to a requirement of 90% similarity is suitable for the invention when the data stream is generated by SELDI-TOF mass spectroscopy data. Mathematically, 90% similarity is defined by requiring that the distance between any two members of a cluster is less than 0.1 of the maximum distance between two points in a normalized vector space. For this calculation, the
15 vector space is normalized so that the range of each scalar of the vectors within the training data set is between 0.0 and 1.0. Thus normalized, the maximal possible distance between any two vectors in the vector space is then root N, where N is the number of dimensions. The Euclidean diameter of each cluster is then $0.1 \times \text{root}(N)$.

The specific normalization of the vector space is not a critical feature of
20 the method. The foregoing method was selected for ease of calculation. Alternative normalization can be accomplished by scaling each dimension not to the range but so that each dimension has an equal variance.

Those skilled in the art will further recognize that the data stream may be converted into logarithmic form if the distribution of values within the data stream is log normal and not normally distributed.

Once the optimal set of data clusters for a logical chromosome has been generated, the fitness score for that chromosome can be calculated. For the present invention, the fitness score of the chromosome roughly corresponds to the number of vectors of the training data set that rest in clusters that are homogeneous, i.e., clusters that contain the characteristic vectors from samples having a single diagnosis. More precisely, the fitness score is calculated by assigning to each cluster a homogeneity score, which varies, for example, from 0.0 for homogeneous clusters to 0.5 for clusters that contain equal numbers of malignant and benign sample vectors. The fitness score of the chromosome is the average fitness score of the data clusters. Thus, a fitness score of 0.0 is the most fit. There is a bias towards logical chromosomes that generate more data clusters, in that when two logical chromosomes that have equal numbers of errors in assigning the data, the chromosome that generates the more clusters will have a lower average homogeneity score and thus a better fitness score.

A preferred technique for generating for generating data clusters is using the self-organizing map algorithm as developed by Kohonen. (Kohonen, T, Self-organizing maps, Springer Verlag, Heidelberg 1997). This type of technique is variously termed a "Lead Cluster Map" ("LCM") or an "Adaptive Feature Map" can be implemented by generic software that is publicly available. Suitable vendors and products include Model 1 from Group One Software (Greenbelt, MD) and Adaptive Fuzzy Feature Map (American Heuristics Corp.). The LCM has significant

advantages in that it is a) it is a non-linear modeling method; b) the number of independent variables is virtually unlimited; and c) compared to other non-linear modeling techniques, the LCM has the advantage of being adaptive. It can detect novel patterns in the data stream and track rare patterns. This is particularly important in classification of biological states, viz, mutations to viruses.

E. Description and Verification of Specific Embodiments

1. Development of a Diagnostic for Prostatic Cancer

Using the above-described learning algorithm, the current invention was employed to develop a diagnostic for prostatic cancer using SELDI-TOF mass spectra (MS) of 55 patient serum samples, 30 having biopsy diagnosed prostatic cancer and prostatic serum antigen (PSA) levels greater than 4.0 ng/ml and 25 normals having PSA levels below 1 ng/ml. The MS data was abstracted by selection of 7 molecular weight values (2092, 2367, 2582, 3080, 4819, 5439 and 18,220 Da). The specific molecular weights are not a critical parameter of the invention and may vary depending on the absorptive surface. A cluster map that assigned each vector in the training data set to a homogeneous data cluster was generated. The cluster map contained 34 clusters, 17 benign and 17 malignant.

The diagnostic algorithm was tested using 231 samples that were excluded from the training data set. Six sets of samples from patients with various clinical and pathological diagnoses were used. The clinical and pathological description and the algorithm results were as follows: 1) 24 patients with PSA >4 ng/ml and biopsy proven cancer, 22 map to diseased data clusters, 2 map to no cluster; 2) 6 normal, all map to healthy clusters; 3) 39 with benign hypertrophy (BPH) or prostatitis and PSA < 4 ng/ml, 7 map to diseased data clusters, none to

healthy data clusters and 32 to no data cluster; 4) 139 with BPH or prostatitis and PSA >4 and <10 ng/ml, 42 map to diseased data clusters, 2 to healthy data clusters and 95 to no data cluster; 5) 19 with BPH or prostatitis and PSA > 10 ng/ml, 9 map to diseased data clusters none to healthy and 10 to no data cluster. A sixth set of data was developed by taking pre- and post-prostatectomy samples from patients having biopsy proven carcinoma and PSA > 10 ng/ml. As expected, each of the 7 pre-surgical samples was assigned to a diseased data set. However, none of the sample taken 6 weeks post surgery, at a time when the PSA levels had fallen to below 1 ng/ml, were not assignable to any data set. These results are summarized in Table 1.

When evaluating the results of the foregoing test, it should be recalled that the rate of occult carcinoma in patients having PSA of 4-10 ng/ml and benign biopsy diagnosis is about 30%. Thus, the finding that between 18% and 47% of the patients with elevated PSA, but no tissue diagnosis of cancer, is consistent with a highly accurate assay that correctly predicts the presence of carcinoma.

Of greater present interest is the fact that the diagnostic algorithm is able to classify a significant fraction of the samples in 3), 4) and 5) to a non-cancerous, non-normal category despite the fact that such category was not presented during training. Indeed, the fact that any samples from this group would necessarily include a substantial number with occult carcinoma carriers argues that BPH or prostatitis samples should not be included in the training data set.

Table 1

STUDY SET	N	PREDICTED PHENOTYPE		
		CANCER (%)	NORMAL (%)	OTHER (%)
Biopsy proven cancer (PSA > 4 ng/ml) ^a	24	22 (92%)	0 (0%)	2 (8%)
Control Men (PSA < 1 ng/ml)	6	0 (0%)	6 (100%)	0 (0%)
Biopsy proven BPH/Prostatitis (PSA < 4 ng/ml)	39	7 (18%)	0 (0%)	32 (82%)
Biopsy proven BPH/Prostatitis ^b (PSA 4-10 ng/ml)	139	42 (30%)	2 (1%)	95 (69%)
Biopsy proven BPH/Prostatitis (PSA > 10 ng/ml)	19	9 (47%)	0 (0%)	10 (52%)
Biopsy proven cancer PRE-SURGERY ^c (PSA > 10 ng/ml)	7	7 (100%)	0 (0%)	0 (0%)
Biopsy proven cancer POST-SURGERY ^{c,d} (PSA < 1 ng/ml)	7	0 (0%)	0 (0%)	7 (100%)

^a Male subjects entered in screening trial; entrance criteria: > 50 years old, asymptomatic. Biopsy conducted if PSA > 4 ng/ml or a positive digital rectal exam. Includes 6 patients with PSA > 10 ng/ml and 18 patients with PSA 4-10 ng/ml.

^b 30-35% occult cancer expected

^c Patient-matched

^d Serum taken at six-week post-surgery follow-up

2. Development of a Diagnostic for Ovarian Cancer

The above described methods were employed to generate a diagnostic algorithm for ovarian carcinoma again using SELDI-TOF MS analysis of patient serum. A training set of 100 samples was used to construct a cluster set map. The MS data was abstracted by selection of 5 molecular weights (531, 681, 903, 1108 and 2863 m/e). A cluster map consisting of 15 disease clusters and 11 healthy clusters was constructed. Of the 50 samples in the training data set having proven ovarian cancer, 40 were assigned to diseased data clusters, leaving 10 false negative; of the 50

samples from normals, 44 were assigned to healthy data clusters leaving 6 false positives.

It was observed that for each of the selected molecular weights, the range of values of the healthy and diseased data clusters overlapped. Indeed, for 4 of the 5 molecular weights, the range for the diseased encompassed the range for the healthy data clusters. Additionally, the diagnostic patterns being detected were not caused by tumor markers, but rather by contextual diagnostic products.

The diagnostic algorithm was tested using a further 100 samples, which were divided into three clinical, pathological groups. The groups and the algorithm results were as follows: 1) 50 samples from patients with no disease, 47 were assigned to healthy data clusters and 3 to disease data clusters; 2) 32 patients with ovarian carcinoma Stages II, III or IV, all of which were assigned to diseased data clusters; and 3) 18 patients with ovarian carcinoma stage I, all of which mapped to diseased data clusters. These results are summarized in Table 2.

Table 2

Cohort	N	Predicted Cancer	Predicted Negative	Accuracy
No Evidence of Disease	50	3	47	94%
Biopsy Proven Ovarian Cancer Stage II, III, IV	32	32	0	100%
Biopsy Proven Ovarian Cancer Stage I	18	18	0	100%

3. Sensitivity for Early Stage Disease

A set of randomly chosen sera (50 from the control cohort and 50 sera from the disease cohort) within the ovarian cancer study set of 200 specimens was

selected for SELDI-TOF mass spectrometry analysis and subsequent training of the bioinformatics method. A pattern of mass intensities at 5 independent molecular weight regions of 534, 989, 2111, 2251, and 2465 Da discovered from a starting set of 15,000⁵ pattern permutations correctly segregated 98% (49/50) of the ovarian cancer samples and 94% of the controls (47/50) in the training set. The optimal proteomic pattern, challenged with 100 SELDI-TOF data streams from diagnosis-blinded cases was able to accurately predict the presence of ovarian cancer in all 50 cancer specimens contained within the 100 unknown test samples (50/50, 95% confidence interval 93% to 100%). This included the correct classification of 18/18 stage I cancers (95% confidence interval 82% to 100%) while maintaining specificity for the blinded cancer-free samples (47/50, 95% confidence interval 84% to 99%, overall $p < 10^{-10}$ by chi-squared test). These results support the hypothesis that low molecular weight proteomic patterns in sera reflect changes in the pathology of tissue within an organ at a distant site. Moreover, such patterns may be sensitive indicators of early pathological changes, since they correctly classified all 18 sera from organ-confined stage I ovarian cancer specimens.

4. Specificity, Prediction and Discrimination of the Presence of Prostate Cancer and Benign Prostate Hypertrophy

Initially, the current invention was challenged to find a pattern of proteins that could discriminate the sera from men with biopsy-proven prostate cancer from sera derived from asymptomatic aged-matched males. The training set was comprised of 56 sera, 31 from asymptomatic men with biopsy-proven prostate cancer (PSA >4 ng/ml, avg. 14.5 ng/ml), and 25 age-matched men with no evidence of prostate cancer (PSA <1 ng/ml, avg. 0.3 ng/ml). The 56 sera were analyzed by

SELDI-TOF. The pattern discovery analysis found a signature pattern of the combined normalized intensities of 7 protein peaks (out of 15,000⁷ possible permutations) at the specific molecular weights of 2092, 2367, 2582, 3080, 4819, 5439, and 18220 Da that could distinguish all 56 samples analyzed in the prostate sera training set.

After training, the optimal proteomic pattern was tested with 227 blinded sera samples. The blinded study set contained a) 24 sera from asymptomatic men who had subsequent biopsy-proven cancer, and whose PSA values were between 4-10 ng/ml at the time of collection, b) control sera from 6 age-matched males (PSA <1 ng/ml) and c) 197 sera from men with biopsy-proven benign prostatic hypertrophy or prostatitis (PSA values ranged from 0.4 ng/ml to 36 ng/ml).

Using the prostate signature pattern, the data-mining tool was able to accurately predict the presence of prostate cancer in the blinded test set (92%, 22/24, $p < 0.000001$ compared to patients with BPH), including 17/18 containing PSA values of 4-10 ng/ml. Importantly 70% of the patients (137/197) with biopsy proven BPH were classified as belonging to a unique (non-normal, non-cancer) phenotype. Only 1% of the sera from the BPH-positive cohort was categorized as a normal phenotype. When sera from 6 healthy controls were compared to those of the 24 patients with biopsy proven cancer, 6/6 healthy patients were classified correctly, compared to 22/24 patients with prostate cancer ($p < 0.000001$). In addition, a statistically significant trend emerged in the relationship between increasing PSA levels (normal, BPH with increasing PSA) and increasing classification of severity of disease ($p = 1.4 \times 10^{-4}$). The optimized prostate signatures reverted from a cancerous to a non-cancerous (but not normal) phenotype in a blinded set of matched sera from patients

who underwent curative prostate resection in 7 of 7 subjects ($p=0.016$; 95% confidence interval 59% to 100%).

5. Sample Source Preparation and Analysis

a. Ovarian Cancer

5 The anonymized ovarian screening serum study set was obtained from the Early Detection Research Network ("EDRN") National Ovarian Cancer Early Detection Program according to full Institutional Review Board ("IRB") oversight. This set contained sera from 200 asymptomatic women, 100 with ovarian cancer at the time of sample collection and 100 control women at risk for ovarian cancer as defined by family history or previous breast cancer diagnosis (Table 3). This group of unaffected women had been followed and was disease-free for at least five years. All sera were obtained prior to diagnosis and intervention. The disease cohort included histology confirmed papillary serous, endometrioid, clear cell, mucinous, adenocarcinoma, and mixed ovarian cancers of all stages. All women in the disease cohort underwent extensive surgical exploration and formal FIGO staging.

Table 3

PANEL SET	Total Patients	Training Subset	Unknown Test Set	DIAGNOSIS
Ovarian Cancer Screening Clinic	100	50	50	No Evidence of disease: 5 year follow up.
	100	50	50	Path Dx: Ovarian Cancer
Prostate Cancer Screening Clinic	31	25	6	No evidence of disease: PSA<1.0 ng/mL
	55	31	24	Path Dx: Prostate Cancer: PSA>4.0 ng/mL
	197	0	197	Path Diagnosis: BPH / Prostatitis
	7	0	7	Biopsy proven cancer PRE-SURGERY
	7	0	7	Biopsy proven cancer Post-SURGERY

b. Prostatic Cancer

The anonymized prostate screening serum study set was obtained from a prostate cancer-screening clinic where samples were obtained under approved informed consent (277 samples) (Table 3). An additional 20 anonymized specimens were collected at the National Cancer Institute under IRB approved informed consent.

5 The Chilean trial was initiated in 1996 and lasted for 5 years. The subject eligibility criteria required asymptomatic men over the age of 50 with no previous history of prostate cancer. All men provided a serum sample and then received a medical evaluation and a digital rectal examination. Subsequently, men with a serum PSA >4.0 ng/ml, or suspicious digital rectal examinations were subjected to a single core
10 needle biopsy for pathologic diagnosis. The prostate adenocarcinomas represented were of a full spectrum of grades (I-III) and Gleason scores (4-9). The 20 sera acquired at the NCI were taken from a) 7 men at the time of diagnosis and six weeks after prostatectomies for biopsy-proven organ confined prostate cancer and b) 6
15 normal healthy male volunteers, PSA < 1.0 ng/ml. All sera were obtained prior to medical examination, diagnosis, and treatment. All sera were collected, spun down, aliquoted and stored in liquid nitrogen until use. Received sera were thawed once, separated into 10 microliter aliquots, and then refrozen in liquid nitrogen until SELDI-TOF analysis was performed.

5. Proteomic analysis

20 Sera were thawed and used once to generate protein mass signatures on the Protein Biology System 1 SELDI-TOF mass spectrometer (Ciphergen Biosystems, Fremont, CA). External mass calibration was accomplished using angiotensin I (amino acid sequence 1-10) and bovine cytochrome c (Ciphergen Biosystems, Fremont, CA) with respective masses of 1296.5Da and 12230.9Da. Protein profiles

of all proteins that can bind to the C18 reverse-phase hydrophobic interaction surface within the 1000-20,000 Da mass range were generated. The organic acid matrix surface was α -cyano-4-hydroxy-cinnamic acid (CHCA). This matrix is required to co-crystallize with the protein mixture for full protein ionization off of the selected bait.

5 Sample preparation: One microliter of acetonitrile (Sigma-Aldrich Co., St. Louis, MO) was added to the sample spots of the 8-feature C18 hydrophobic interaction protein chip (CIPHERGEN Biosystems, Inc., Fremont, CA). This chip will bind proteins through hydrophobic interactions that are dependent upon the intrinsic primary amino acid sequences specific for every protein. The acetonitrile application
10 was followed by the addition of 1 μ l of serum. The sample was allowed to air dry on the chip. The chips were vigorously washed by vortexing in deionized water for 4 minutes and allowed to air dry. Lastly, 0.5 μ l of CHCA solution was added. After the matrix solution dried, an additional 0.5 μ l of matrix was applied to each sample and allowed to air dry. The C18 chip was chosen because it was found to consistently and
15 reproducibly produce the greatest number of different protein and peptide signatures (data not shown). SELDI-TOF, like other time-of-flight spectrometric techniques, has its best sensitivity at the low molecular weight range (< 20,000 Da). Data were recorded and optimized for analysis with the SELDI Protein Biology System version 2.0 software (CIPHERGEN Biosystems, Inc., Palo Alto, CA). Raw SELDI data, not
20 filtered or scaled in any way, were converted to ASCII data files for analysis by the data-mining tool.

6. Detection of Drug Toxicity

The method of the invention was tested on data streams obtained from biological samples from rats treated with doxorubicin that developed proven

cardiotoxicity. Controls were treated with saline. The biological samples obtained from rats showing cardiotoxicity were classified correctly with 100% selectivity and 100% sensitivity and no false positives. See Table 4.

Table 4.

Count - Actual	Actual		
Score	0	1	Total Result
0	29		29
1	1	7	8
Total Result	30	7	37

Sensitivity 100.00%
Selectivity 0.00%

5 7. Detection of Drug Treatment

Rats were treated with doxorubicin and a cardioprotectant. Thus, some animals had toxicity while others did not. Table 8 shows that using the method of the invention all but one of the treated animals could be correctly identified, while only misclassifying 2 control animals. See Table 5.

10

Table 5.

Count - Actual	Actual		
Score	0	1	Total Result
0	15		15
0.1	10	1	11
0.56	2	4	6
1		13	13
Total Result	27	18	45
@ Score = 0.56	Sensitivity	94.44%	
	Selectivity	10.53%	

8. Detection of Virus

Simian Foamy Virus was detected in cell lysates. Lysates from infected cells were correctly classified 80% of the time (8/10) with no false positives.

15 See Table 6.

Table 6.

Count - Actual	Actual		
Score	0	1	Total Result
0	9		9
0.5	3	2	5
0.8		6	6
1		2	2
Total Result	12	10	22
@ Score =0.8	Sensitivity	80.00%	
	Selectivity	0.00%	

9. Use of a Windowing Technique for Ovarian Cancer

Initial reduction to practice was based on a simple trial and error

- 5 selection of groups of 100 contiguous features in the proteomic data stream. An adaptive pattern recognition algorithm, the Lead Cluster Map, (LCM) was employed. Sampling of the data stream started at a different point in the data stream for each run. A run consisted of collection of 14-15 collections of 100 features. After a series of 25 runs, the best models accurately predicted the correct biological state 80% with a false
- 10 positive rate of approximately 30 %. These results demonstrate the effectiveness of using proteomic patterns in the classification of biological states. Indeed, models with this level of accuracy would be well suited for batch screening of potentially therapeutic compounds. See Table 7.

Table 7

Count - Actual	Actual		
Score	0	1	Total Result
0	18	3	21
0.25	10	1	11
0.29	5	6	11
0.33	5	5	10
0.5	6	6	12
0.67	2	11	13
1	4	18	22
Total Result	50	50	100
	Sensitivity @ 0.33		80%
	Specificity @ 0.33		29.82%

10. Detection of Breast Cancer

Nipple aspirants taken from breast cancer patients were analyzed using the process of the invention. The nipple aspirants were subjected to a mass spectral analysis and subjected to a pattern finding method. A sensitivity of nearly 92% was observed. See Table 8.

Table 8.

Count - Actual	Actual		
Score	0	1	Total Result
0	7	2	9
0.5	3		3
0.67		5	5
1		6	6
Total Result	10	13	23
	Sensitivity @ 0.67		91.67%
	Selectivity @ 0.67		0.00%

In the Claims

1. A method of classifying a biological state from biological data by the detection of discriminatory patterns where the discriminatory pattern describes the biological state.
2. A method of classifying a biological state from biological data by the steps of:
 - a. detecting a discriminatory pattern that is a subset of a larger set of data in a data stream, said discrimination defined by success in a learning set of data;
 - b. applying said discriminatory pattern to classify known or test data samples; and
 - c. using said discriminatory pattern to classify unknown data samples, wherein the discriminatory pattern is indicative of the biological state and is discriminatory even when individual data points are not.
3. A method of classifying a biological state in biological data by the detection of discriminatory patterns using a vector space having multiple predetermined diagnostic clusters defining a known biological state comprising the steps of :
 - a. forming a normalized data stream that describes the biological data;
 - b. abstracting the data stream to calculate a sample vector that characterizes the data stream;
 - c. identifying the diagnostic cluster, if any, within which the sample vector rests;
 - d. assigning to the biological data the diagnosis of the identified diagnostic cluster or, if no cluster is identified, assigning to the biological data the diagnosis of atypical sample, NOS; and

- e. using said discriminatory pattern to classify unknown data samples, wherein the discriminatory pattern describes the biological state and is discriminatory even when individual data points are not.
4. The method of claims 1, 2, or 3, wherein the discrimination is defined by success in a learning set of data, said learning set of data formed from biological data for which the biological state is known.
 5. The method of claims 1, 2, or 3, wherein the biological data is data describing the expression of molecules in a biological sample.
 6. The method of claims 1, 2, or 3, wherein the biological data is derived from clinical data.
 7. The method of claims 1, 2, or 3, wherein the biological data is any combination of clinical data and data describing the expression of molecules in a biological sample.
 8. The method of claims 1, 2, or 3, wherein the biological data is any combination of non-biological data and data describing the expression of molecules in a biological sample.
 9. The method of claim 5 wherein the molecules are selected from the group consisting of proteins, peptides, phospholipids, DNA, and RNA.
 10. The method of claim 7 wherein the molecules are selected from the group consisting of proteins, peptides, phospholipids, DNA, and RNA.
 11. The method of claim 8 wherein the molecules are selected from the group consisting of proteins, peptides, phospholipids, DNA, and RNA.
 12. The method of claim 5, wherein the biological sample is selected from the group consisting of serum, blood, saliva, plasma, nipple aspirants, synovial

- fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, and pre-ejaculate.
13. The method of claim 7, wherein the biological sample is selected from the group consisting of any bodily fluid such as serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, and pre-ejaculate.
 14. The method of claim 8, wherein the biological sample is selected from the group consisting of any bodily fluid such as serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, and pre-ejaculate.
 15. The method of claim 5, wherein the biological sample is selected from the group consisting of tissue culture supernatants, lyophilized tissue cultures, and viral cultures.
 16. The method of claim 7, wherein the biological sample is selected from the group consisting of tissue culture supernatants, lyophilized tissue cultures, and viral cultures.
 17. The method of claim 8, wherein the biological sample is selected from the group consisting of tissue culture supernatants, lyophilized tissue cultures, and viral cultures.
 18. The method of claims 1, 2, or 3, wherein the biological state is a disease.
 19. The method of claims 1, 2, or 3, wherein the biological state is a stage of a disease.

20. The method of claims 1, 2, or 3, wherein the biological state is the prognosis of a disease.
21. The method of claims 1, 2, or 3, wherein the biological state is the disease of an internal body organ.
22. The method of claims 1, 2, or 3, wherein the biological state is the stage of a disease of an internal body organ.
23. The method of claims 1, 2, or 3, wherein the biological state is the health of an internal body organ.
24. The method of claims 1, 2, or 3, wherein the biological state is the toxicity of one or more chemicals.
25. The method of claims 1, 2, or 3, wherein the biological state is the relative toxicity of one or more chemicals.
26. The method of claims 1, 2, or 3, wherein the biological state is the efficacy of a drug.
27. The method of claims 1, 2, or 3, wherein the biological state is the efficacy of one or more drugs.
28. The method of claims 1, 2, or 3, wherein the biological state is the responsiveness to a regimen of therapy.
29. The method of claims 1, 2, or 3, wherein the biological state is the state of perturbation of a body organ.
30. The method of claim 1, 2, or 3, wherein the biological state is the presence of one or more pathogens.

31. The method of claim 18, wherein the disease is one in which changes in the patterns of expression of inherent molecules in the diseased state are different from the non-diseased state.
32. The method of claim 18, wherein the disease is a cancer.
33. The method of claim 18, wherein the disease is selected from the group consisting of auto-immune diseases, Alzheimer's disease and arthritis.
34. The method of claim 18, wherein the disease is glomerulonephritis.
35. The method of claim 18, wherein the disease is any infectious disease.
36. The method of claim 32, wherein the cancer is selected from the group consisting of carcinomas, melanomas, lymphomas, sarcomas, blastomas, leukemias, myelomas, and neural tumors.
37. The method of claim 37, wherein the carcinoma is a prostatic carcinoma.
38. The method of claim 36, wherein the carcinoma is ovarian carcinoma.
39. The method of claims 2 or 3, wherein the data stream is formed by any high throughput data generation method.
40. The method of claims 2 or 3, wherein the data stream is a time of flight mass spectrum.
41. The method of claim 40, wherein the time of flight mass spectrum is generated by surface-enhanced laser desorption time-of-flight mass spectroscopy.
42. The method of claim 40, wherein the time of flight mass spectrum is generated by matrix assisted laser desorption ionization time of flight.
43. The method of claims 1, 2, or 3, further comprising using any pattern recognition method.

44. The method of claim 43, wherein the pattern recognition method further comprises a learning algorithm and a diagnostic algorithm.
45. The method of claims 1, 2, or 3, further comprising using a set of learning data streams to construct a diagnostic algorithm for a biological state of interest, wherein the diagnostic algorithm is characterized by having multiple diagnostic clusters of predetermined equal size in a vector space of a fixed number of dimensions, comprising the steps of:
- a. providing a set of learning data streams, each data stream describing a biological sample with a known biological state;
 - b. selecting an initial set of random logical chromosomes that specify the location of a predetermine number of points of the data stream;
 - c. calculating a vector for each chromosome and for each data stream by abstracting the data stream at locations specified by the chromosome;
 - d. determining a fitness of each chromosome by finding the locations in the vector space of a multiplicity of non-overlapping data clusters of the predetermined, equal size that maximize the number of vectors that rest in a cluster having a uniform status, wherein the larger the number of such vectors the larger the fitness;
 - e. optimizing the set of logical chromosomes by an iterative process comprising reiteration of steps (c) and (d), terminating logical chromosomes with low fitness, replicating logical chromosomes of high fitness, recombination and random modification of the chromosomes;

- f. terminating the iterative process and selecting a logical chromosome that allows for a preferred set of non-overlapping data clusters; and
 - g. constructing a diagnostic algorithm that embodies the selected logical chromosome and homogeneous non-overlapping data clusters.
- 46. The method of claim 45, further comprising the step of testing a diagnostic algorithm embodying an optimized chromosome and a fitness-maximizing set of data clusters to determine how accurately the diagnostic algorithm diagnoses a test set of data streams each having a known diagnosis that is independent of the instructional data streams.
- 47. The method of claim 45 wherein the vector space contains between 5 and 10 dimensions.
- 48. A method of diagnosing the disease of an organ of an individual which comprises:
 - a. analyzing a biological sample from the subject and calculating from the analysis a normalized vector, having at least 4 scalars and not more than 20 scalars, that is characteristic of the sample;
 - b. providing a vector space of between 4 and 20 dimensions occupied by a data cluster map comprising at least 6 equal-sized, non-overlapping data clusters, a multiplicity of which data clusters are associated with a disease diagnosis and a multiplicity of which data clusters are associated with a normal samples and no data cluster of said map is associated with more than one diagnosis;
 - c. calculating in which, if any, of the data clusters of the data cluster map the characteristic vector rests; and

- d. assigning to the sample the disease diagnosis associated with the data cluster in which the characteristic vector rests or, if the vector rests in no cluster assigning a classification of non-normal.
49. A method of diagnosing the stage of a disease of an organ of an individual which comprises:
- a. analyzing a biological sample from the subject and calculating from the analysis a normalized vector, having at least 4 scalars and not more than 20 scalars, that is characteristic of the sample;
 - b. providing a vector space of between 4 and 20 dimensions occupied by a data cluster map comprising at least 6 equal-sized, non-overlapping data clusters, a multiplicity of which data clusters are associated with a disease diagnosis and a multiplicity of which data clusters are associated with a normal samples and no data cluster of said map is associated with more than one diagnosis;
 - c. calculating in which, if any, of the data clusters of the data cluster map the characteristic vector rests; and
 - d. assigning to the sample the disease diagnosis associated with the data cluster in which the characteristic vector rests or, if the vector rests in no cluster assigning a classification of non-normal.
50. The method of claim 48, wherein the disease is a cancer.
51. The method of claim 49, wherein the disease is a cancer.
52. The method of claim 49, wherein the stage of the disease is a primary malignancy.

53. The method of claims 48 or 49, wherein the biological sample is selected from the group consisting of any bodily fluid such as serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, and pre-ejaculate.
54. The method of claims 48 or 49 wherein the data cluster map defines a pattern, wherein at least one scalar of the vector is a contextual diagnostic product.
55. The method of claims 48 or 49, wherein the size of the data cluster is defined by a Euclidean metric.
56. A method of diagnosing a primary malignancy of an organ of a subject which comprises:
 - a. analyzing a biological sample from the subject and calculating from the analysis a normalized vector, having at least 4 scalars, that is characteristic of the sample;
 - b. providing a vector space of occupied by a data cluster map comprising at least 6 equal-sized, non-overlapping data clusters, a multiplicity of which data clusters are associated with a malignant diagnosis and a multiplicity of which data clusters are associated with a benign diagnosis and no data cluster of said map is associated with more than one diagnosis, wherein at least one scalar measures a product that is a contextual diagnostic product and wherein the size of the data cluster is defined by a Euclidean metric;
 - c. calculating in which, if any, of the data clusters of the data cluster map the characteristic vector rests; and

- d. assigning to the sample the diagnosis associated with the data cluster in which the characteristic vector rests or if the vector rest in no data cluster assigning a diagnosis of non-normal, non-malignant.
57. The method of claim 56, wherein the biological sample is selected from the group consisting of any bodily fluid such as serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate.
58. The method of claim 56, wherein the a multiplicity of scalars measure products that are contextual diagnostic products.
59. A computer software product that specifies computer executable code to execute a program comprising the following steps:
- a. inputting a normalized data stream that describes a biological sample with a sample identifier;
 - b. inputting a set of diagnostic clusters, each cluster associated with a diagnosis of a known biological state;
 - c. abstracting the data stream to calculate a sample vector that characterizes the data stream;
 - d. identifying the diagnostic cluster, if any, within which the sample vector falls;
 - e. assigning to the sample the diagnosis of the identified diagnostic cluster or, if no cluster is identified assigning to the sample the diagnosis of non-normal, non-malignant; and
 - f. outputting the assigned diagnosis and the sample identifier.

60. A general purpose digital computer comprising a program to execute the executable code of claim 59.
61. A computer software product that specifies computer executable code to execute a program comprising the following steps:
 - a. inputting a set of instructional data streams, each data stream describing a biological sample with a known biological state;
 - b. inputting an operator specified number of points and an operator specified cluster size;
 - c. selecting an initial set of random logical chromosomes that specify the location of the pre-specified number of points of the data stream;
 - d. calculating a vector for each chromosome and for each data stream by abstracting the data stream at locations specified by the chromosome;
 - e. determining a fitness of each chromosome by finding the locations in the vector space of a multiplicity of non-overlapping data clusters of the pre-specified size that maximize the number of vectors that rest in clusters having a uniform status, wherein the larger the number of such vectors the higher the fitness;
 - f. optimizing the set of logical chromosomes by an iterative process comprising reiteration of steps (d) and (e), terminating logical chromosomes with low fitness, replicating logical chromosomes of high fitness, recombination and random modification of the chromosomes;
 - g. terminating the iterative process; and

- h. outputting an optimized logical chromosome, and the locations of the data clusters that maximize the fitness of the optimized chromosome, so that a diagnostic algorithm that embodies the outputted logical chromosome and data clusters can be implemented.
62. A general purpose digital computer comprising a program to execute the executable code of claim 61.
63. A diagnostic model to determine a biological state of interest, wherein the diagnostic algorithm is characterized by having multiple diagnostic clusters of predetermined equal size in a vector space of a fixed number of dimensions.
64. The diagnostic model of claim 63, wherein the diagnostic clusters are produced by the following steps:
- a. providing a set of learning data streams, each data stream describing a biological sample with a known biological state;
 - b. selecting an initial set of random logical chromosomes that specify the location of a predetermine number of points of the data stream;
 - c. calculating a vector for each chromosome and for each data stream by abstracting the data stream at locations specified by the chromosome;
 - d. determining a fitness of each chromosome by finding the locations in the vector space of a multiplicity of non-overlapping data clusters of the predetermined, equal size that maximize the number of vectors that rest in a cluster having a uniform status, wherein the larger the number of such vectors the larger the fitness;
 - e. optimizing the set of logical chromosomes by an iterative process comprising reiteration of steps (c) and (d), terminating logical

chromosomes with low fitness, replicating logical chromosomes of high fitness, recombination and random modification of the chromosomes;

- f. terminating the iterative process and selecting a logical chromosome that allows for a preferred set of non-overlapping data clusters.

65. The diagnostic clusters produced by the model of claim 64.